News headlines about Organovo (NASDAQ:ONVO) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.8165402758208 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Will Shareholder Love To Invest in This Stock? (nasdaqjournal.com)
- Organovo Holdings, Inc. (ONVO) expected to achieve earnings growth of 8.20% for this year (wallstreetinvestorplace.com)
- Summary of what has been trade about Organovo Holdings, Inc. (ONVO) (wallstreetmorning.com)
- Are you searching Analysts Rated Stock: Organovo Holdings, Inc. (ONVO) (wallstreetmorning.com)
- Edited Transcript of ONVO earnings conference call or presentation 8-Feb-18 10:00pm GMT (finance.yahoo.com)
Separately, Zacks Investment Research cut Organovo from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.40.
Organovo (NASDAQ:ONVO) last announced its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $1.25 million. During the same quarter last year, the firm posted ($0.09) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. research analysts predict that Organovo will post -0.33 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Organovo (NASDAQ:ONVO) Getting Somewhat Positive Press Coverage, Study Finds” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/04/06/organovo-onvo-receiving-somewhat-favorable-press-coverage-study-shows/2030295.html.
Organovo Company Profile
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.